Vident Investment Advisory’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Vident Investment Advisory’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,199	Closed	-$476K	–	1370
2023 Q1	$476K	Sell	25,199 -869	-3%	-$20.2K	0.02%	794
2022 Q4	$642K	Buy	+26,068	New	+$766K	0.02%	631
2022 Q2	–	Sell	-26,940	Closed	-$600K	–	1404
2022 Q1	$600K	Buy	26,940 +4,490	+20%	+$115K	0.02%	877
2021 Q4	$980K	Buy	+22,450	New	+$898K	0.03%	716

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Vident Investment Advisory's INBX Position: Q2 2023 in Review

Vident Investment Advisory sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2023, closing a stake of 25,199 shares — an estimated $476K sold.

Vident Investment Advisory first reported a position in INBX in Q4 2021 and held it in 4 quarters. The position peaked at $980K in Q4 2021. 107 funds tracked by Wall St. Rank hold INBX as of Q2 2023.

Vident Investment Advisory reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Vident Investment Advisory sold 25,199 Inhibrx, Inc. Common Stock shares in Q2 2023, an estimated $476K.
Vident Investment Advisory first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Vident Investment Advisory's Inhibrx, Inc. Common Stock position peaked at $980K in Q4 2021.
107 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.